Merck's Supplemental New Drug Application for Welireg Granted Priority Review by FDA
MT Newswires Live01-27
Merck (MRK) said Monday that the US Food and Drug Administration has granted priority review to the supplemental new drug application for Welireg, also known as belzutifan, as a treatment for adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
The company said the application was based on the objective response rate and duration of response data from a phase 2 trial of Welireg, which will be presented at an upcoming medical meeting.
According to Merck, the FDA has set a target action date of May 26 for the application.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
